Does the media favor NBIX or INDV?

In the previous week, Neurocrine Biosciences had 8 more articles in the media than Indivior. MarketBeat recorded 35 mentions for Neurocrine Biosciences and 27 mentions for Indivior. Indivior's average media sentiment score of 0.83 beat Neurocrine Biosciences' score of 0.77 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 15 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer INDV or JAZZ?

In the previous week, Jazz Pharmaceuticals had 7 more articles in the media than Indivior. MarketBeat recorded 34 mentions for Jazz Pharmaceuticals and 27 mentions for Indivior. Indivior's average media sentiment score of 0.83 beat Jazz Pharmaceuticals' score of 0.52 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Jazz Pharmaceuticals 10 Very Positive mention(s) 7 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELAN or INDV?

In the previous week, Elanco Animal Health had 4 more articles in the media than Indivior. MarketBeat recorded 31 mentions for Elanco Animal Health and 27 mentions for Indivior. Indivior's average media sentiment score of 0.83 beat Elanco Animal Health's score of 0.81 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 12 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer CORT or INDV?

In the previous week, Indivior had 4 more articles in the media than Corcept Therapeutics. MarketBeat recorded 27 mentions for Indivior and 23 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.91 beat Indivior's score of 0.83 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 15 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer AXSM or INDV?

In the previous week, Indivior had 13 more articles in the media than Axsome Therapeutics. MarketBeat recorded 27 mentions for Indivior and 14 mentions for Axsome Therapeutics. Indivior's average media sentiment score of 0.83 beat Axsome Therapeutics' score of 0.59 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Indivior (INDV) Competitors

$38.82 +0.15 (+0.39%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$37.74 -1.08 (-2.77%)

As of 08/7/2026 07:34 PM Eastern

Compare

INDV vs. NBIX, JAZZ, ELAN, CORT, and AXSM

Should you buy Indivior stock or one of its competitors? MarketBeat compares Indivior with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Indivior include Neurocrine Biosciences (NBIX), Jazz Pharmaceuticals (JAZZ), Elanco Animal Health (ELAN), Corcept Therapeutics (CORT), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceuticals" industry.

How does Indivior compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, Neurocrine Biosciences had 8 more articles in the media than Indivior. MarketBeat recorded 35 mentions for Neurocrine Biosciences and 27 mentions for Indivior. Indivior's average media sentiment score of 0.83 beat Neurocrine Biosciences' score of 0.77 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	15 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Neurocrine Biosciences has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.81	$478.60M	$6.82	23.96
Indivior	$1.33B	3.44	$210M	$2.79	13.91

Indivior has a net margin of 26.65% compared to Neurocrine Biosciences' net margin of 20.91%. Neurocrine Biosciences' return on equity of 22.43% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Indivior	26.65%	-283.11%	36.85%

Neurocrine Biosciences has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Indivior has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

Neurocrine Biosciences currently has a consensus price target of $201.50, indicating a potential upside of 23.31%. Indivior has a consensus price target of $45.17, indicating a potential upside of 16.35%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Neurocrine Biosciences is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Neurocrine Biosciences beats Indivior on 13 of the 17 factors compared between the two stocks.

How does Indivior compare to Jazz Pharmaceuticals?

Indivior (NASDAQ:INDV) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

In the previous week, Jazz Pharmaceuticals had 7 more articles in the media than Indivior. MarketBeat recorded 34 mentions for Jazz Pharmaceuticals and 27 mentions for Indivior. Indivior's average media sentiment score of 0.83 beat Jazz Pharmaceuticals' score of 0.52 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	10 Very Positive mention(s)	7 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

60.3% of Indivior shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 0.7% of Indivior shares are held by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Indivior has a net margin of 26.65% compared to Jazz Pharmaceuticals' net margin of 20.45%. Jazz Pharmaceuticals' return on equity of 33.97% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Indivior has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Indivior presently has a consensus target price of $45.17, suggesting a potential upside of 16.35%. Jazz Pharmaceuticals has a consensus target price of $272.74, suggesting a potential upside of 6.31%. Given Indivior's higher probable upside, equities analysts clearly believe Indivior is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95

Indivior has higher earnings, but lower revenue than Jazz Pharmaceuticals. Indivior is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.33B	3.44	$210M	$2.79	13.91
Jazz Pharmaceuticals	$4.60B	3.62	-$356.15M	$14.50	17.69

Summary

Jazz Pharmaceuticals beats Indivior on 11 of the 17 factors compared between the two stocks.

How does Indivior compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

Elanco Animal Health currently has a consensus target price of $29.09, suggesting a potential upside of 31.88%. Indivior has a consensus target price of $45.17, suggesting a potential upside of 16.35%. Given Elanco Animal Health's higher probable upside, analysts plainly believe Elanco Animal Health is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Indivior has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.34	-$232M	-$0.41	N/A
Indivior	$1.33B	3.44	$210M	$2.79	13.91

In the previous week, Elanco Animal Health had 4 more articles in the media than Indivior. MarketBeat recorded 31 mentions for Elanco Animal Health and 27 mentions for Indivior. Indivior's average media sentiment score of 0.83 beat Elanco Animal Health's score of 0.81 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	12 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Elanco Animal Health has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Indivior has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Indivior has a net margin of 26.65% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Indivior	26.65%	-283.11%	36.85%

Summary

Elanco Animal Health beats Indivior on 9 of the 17 factors compared between the two stocks.

How does Indivior compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Indivior had 4 more articles in the media than Corcept Therapeutics. MarketBeat recorded 27 mentions for Indivior and 23 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.91 beat Indivior's score of 0.83 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	15 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Corcept Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Indivior has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

Corcept Therapeutics currently has a consensus target price of $119.17, suggesting a potential upside of 7.58%. Indivior has a consensus target price of $45.17, suggesting a potential upside of 16.35%. Given Indivior's stronger consensus rating and higher possible upside, analysts clearly believe Indivior is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Indivior has a net margin of 26.65% compared to Corcept Therapeutics' net margin of 6.52%. Corcept Therapeutics' return on equity of 8.26% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Indivior	26.65%	-283.11%	36.85%

Indivior has higher revenue and earnings than Corcept Therapeutics. Indivior is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	15.73	$99.65M	$0.42	263.74
Indivior	$1.33B	3.44	$210M	$2.79	13.91

Summary

Indivior beats Corcept Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Indivior compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Indivior has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.15	-$183.17M	-$3.73	N/A
Indivior	$1.33B	3.44	$210M	$2.79	13.91

Axsome Therapeutics presently has a consensus price target of $265.55, suggesting a potential upside of 24.82%. Indivior has a consensus price target of $45.17, suggesting a potential upside of 16.35%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Axsome Therapeutics is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.91
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Indivior had 13 more articles in the media than Axsome Therapeutics. MarketBeat recorded 27 mentions for Indivior and 14 mentions for Axsome Therapeutics. Indivior's average media sentiment score of 0.83 beat Axsome Therapeutics' score of 0.59 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Axsome Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Indivior has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

Indivior has a net margin of 26.65% compared to Axsome Therapeutics' net margin of -26.59%. Axsome Therapeutics' return on equity of -267.16% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Indivior	26.65%	-283.11%	36.85%

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Indivior beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Indivior News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDV vs. The Competition

Export

Metric	Indivior	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.58B	$11.82B	$7.02B	$13.01B
Dividend Yield	N/A	2.70%	2.58%	10.20%
P/E Ratio	13.91	790.97	270.57	25.03
Price / Sales	3.44	739.17	599.42	84.81
Price / Cash	14.27	15.12	28.89	37.44
Price / Book	-49.77	10.28	11.21	6.43
Net Income	$210M	$2.78B	$3.45B	$348.10M
7 Day Performance	-2.97%	3.36%	4.67%	4.41%
1 Month Performance	-6.00%	-0.81%	-1.28%	-1.11%
1 Year Performance	76.45%	192.86%	77.33%	23.99%

Indivior Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDV Indivior	3.7168 of 5 stars	$38.82 +0.4%	$45.17 +16.3%	+76.5%	$4.58B	$1.33B	13.91	1,051	Trending News Earnings Report Analyst Forecast Analyst Revision
NBIX Neurocrine Biosciences	4.8884 of 5 stars	$168.07 +1.1%	$201.50 +19.9%	+30.7%	$16.91B	$3.37B	24.66	2,000	Analyst Downgrade
JAZZ Jazz Pharmaceuticals	3.1846 of 5 stars	$257.15 +2.2%	$265.00 +3.1%	+130.5%	$16.17B	$4.44B	N/A	2,890	Trending News Earnings Report Analyst Forecast Insider Trade
ELAN Elanco Animal Health	4.3337 of 5 stars	$25.75 +0.1%	$28.73 +11.6%	+32.8%	$12.68B	$4.72B	N/A	9,400	News Coverage Positive News Earnings Report Analyst Forecast
CORT Corcept Therapeutics	3.5632 of 5 stars	$112.05 -0.7%	$119.17 +6.4%	+53.2%	$12.09B	$761.41M	266.21	300	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDV) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indivior (INDV) Competitors

INDV vs. NBIX, JAZZ, ELAN, CORT, and AXSM

How does Indivior compare to Neurocrine Biosciences?

Summary

How does Indivior compare to Jazz Pharmaceuticals?

Summary

How does Indivior compare to Elanco Animal Health?

Summary

How does Indivior compare to Corcept Therapeutics?

Summary

How does Indivior compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indivior (INDV) Competitors

INDV vs. NBIX, JAZZ, ELAN, CORT, and AXSM

How does Indivior compare to Neurocrine Biosciences?

Does the media favor NBIX or INDV?

Which has better valuation and earnings, NBIX or INDV?

Is NBIX or INDV more profitable?

Which has more volatility & risk, NBIX or INDV?

Do analysts rate NBIX or INDV?

Do institutionals & insiders have more ownership in NBIX or INDV?

Summary

How does Indivior compare to Jazz Pharmaceuticals?

Does the media prefer INDV or JAZZ?

Do institutionals and insiders have more ownership in INDV or JAZZ?

Is INDV or JAZZ more profitable?

Which has more risk & volatility, INDV or JAZZ?

Do analysts recommend INDV or JAZZ?

Which has better earnings and valuation, INDV or JAZZ?

Summary

How does Indivior compare to Elanco Animal Health?

Do analysts prefer ELAN or INDV?

Which has stronger valuation and earnings, ELAN or INDV?

Does the media favor ELAN or INDV?

Which has more risk & volatility, ELAN or INDV?

Do insiders & institutionals hold more shares of ELAN or INDV?

Is ELAN or INDV more profitable?

Summary

How does Indivior compare to Corcept Therapeutics?

Do institutionals and insiders have more ownership in CORT or INDV?

Does the media prefer CORT or INDV?

Which has more volatility & risk, CORT or INDV?

Do analysts rate CORT or INDV?

Is CORT or INDV more profitable?

Which has better earnings and valuation, CORT or INDV?

Summary

How does Indivior compare to Axsome Therapeutics?

Which has higher valuation and earnings, AXSM or INDV?

Do analysts rate AXSM or INDV?

Does the media prefer AXSM or INDV?

Which has more risk and volatility, AXSM or INDV?

Is AXSM or INDV more profitable?

Do institutionals & insiders have more ownership in AXSM or INDV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools